Bernstein analyst Eve Burstein initiated coverage of Exact Sciences with an Outperform rating and $83 price target. The analyst says the U.S. life science tools and diagnostics has the same positives as other healthcare sub-sectors, like enduring growth drivers, customers with locked-in processes, increasingly higher-margin / higher recurring revenue, and positive price, as well as a few of the negatives, like high levels of risk from pharma’s patent cliffs and managed care mis-pricing. The firm views Illumina as the relative “loser” in next-generation gene sequencing and calls Guardant its top pick among the molecular diagnostics companies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXAS:
- Exact Sciences’ testing laboratory selected by the National Cancer Institute
- Exact Sciences CFO sells $2.5M in common stock
- Exact Sciences price target raised to $90 from $80 at Piper Sandler
- Exact Sciences price target raised to $110 from $100 at Jefferies
- AMD upgraded, Electronic Arts downgraded: Wall Street’s top analyst calls